Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.19Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -20.69%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
OmniAb exhibited strong growth in active partnerships and revenue, highlighting the positive reception of their technologies and notable advancements in their pipeline. However, the decline in service revenue, impairment charges, and reduced revenue guidance for 2025 present challenges. The overall sentiment is cautiously optimistic, with a balanced view of achievements and obstacles.Company Guidance
During the call, OmniAb Inc. provided guidance for 2025, projecting total revenue to be in the range of $20 million to $25 million. The company reported an 18% year-over-year growth in active partners, reaching 91 as of December 31, 2024, and a 12% increase in active programs, totaling 362 net of attrition. OmniAb anticipates 5 to 7 new entries into clinical development in 2025, with 32 active clinical programs and approved products currently in place. Operating expenses for 2025 are expected to decrease, with a forecasted range of $90 million to $95 million, and the company aims to reduce cash use compared to 2024. The effective tax rate is expected to be around 0% due to a valuation allowance offsetting the tax benefit associated with the net loss.Significant Revenue Growth
Total revenue increased to $10.8 million in Q4 2024 from $4.8 million in Q4 2023, primarily driven by higher license and milestone revenue due to new deals and clinical advancements.
Increase in Active Partners and Programs
Active partners grew by 18% to 91, and active programs increased by 12% to 362 as of December 31, 2024, showcasing strong industry interest in OmniAb's technologies.
Strong Pipeline Development
Five new OmniAb-derived programs entered clinical trials in 2024, with potential for 5 to 7 new entries in 2025, indicating a robust pipeline.
Financial Stability
OmniAb exited 2024 with $59.4 million in cash, at the top end of the guidance range provided in the last earnings call.
Positive Partner Developments
Genmab's Acasunlimab, Teva's pipeline, and Immunovant’s IMVT-1402 and Batoclimab highlight promising developments with significant market opportunities.
---
OABI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OABI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $3.19 | $2.54 | -20.38% |
| Nov 12, 2024 | $4.49 | $4.07 | -9.35% |
| Aug 08, 2024 | $4.29 | $4.24 | -1.17% |
| May 09, 2024 | $4.57 | $4.68 | +2.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does OmniAb (OABI) report earnings?
OmniAb (OABI) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is OmniAb (OABI) earnings time?
OmniAb (OABI) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OABI EPS forecast?
OABI EPS forecast for the fiscal quarter 2025 (Q1) is -0.16.
---